Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
15.9.2022 17:00:00 EEST | Business Wire | Press release
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini- CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
Contact information
For further information:
Caravan Biologix, Inc.:
Jeff Riley
CEO
+1.917.510.3773
jeff@caravanbio.com
MDimune Inc.
Seung Wook Oh, Ph.D.:
CSO
+82-2-2655-2636
swoh@mdimune.com; Info@biodroneus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreviPay Research Tracks the Evolution of B2B Buyer Expectations as AI Reshapes the Purchasing Process20.5.2026 15:00:00 EEST | Press release
New research from TreviPay, a global B2B payments infrastructure partner, found 88% of B2B buyers report high loyalty to their suppliers, consistent with TreviPay’s 2023 research. In 2026, buyers now place greater decision power on how efficiently and consistently suppliers deliver across the purchasing, payment and invoicing experience, meaning their loyalty is dependent on how well a supplier can execute. TreviPay’s latest report, The Evolution of the B2B Buyer, builds on the company’s 2023 B2B buyer research and examines how expectations have evolved across payments, onboarding, invoice terms, automation and supplier relationships. Key findings include: AI integration and digital maturity are reshaping purchasing. Seventy-three percent of buyers now use AI in purchasing workflows, showing automation has moved from exploration into everyday decision-making. Demand for financial terms has reached a tipping point. The likelihood of choosing a supplier that offers invoice terms increase
Ennov Announces Strategic Growth Investment from Bregal Sagemount and Ardian20.5.2026 15:00:00 EEST | Press release
Ennov (the “Company”), a global provider of end-to-end regulatory, quality, and clinical software solutions for life sciences and healthcare companies, today announced a strategic growth investment led by Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, with participation from Ardian, a global private investment firm. The investment will support the Company’s continued expansion, with a focus on AI innovation, global go-to-market acceleration, and scaling its product offering. Founded and headquartered in Paris, Ennov provides a unified compliance platform that serves as a centralized system of record for global life sciences organizations. The platform supports the management of content and data across key domains, including Regulatory, Quality, Commercial, Clinical, and Pharmacovigilance. Its integrated architecture and unified data model enable faster deployment, improved user adoption, consistent compliance, and AI-driven efficiency across global operat
Thales Announces Strategic Partnership with Google Cloud to Launch a New Sovereign Cloud in Germany20.5.2026 14:54:00 EEST | Press release
Thales, a global leader in high technologies, today announced a strategic partnership with Google Cloud to establish a new sovereign cloud solution in Germany. Building on the success of S3NS, Thales’ trusted cloud subsidiary in France, and operator of its first European sovereign cloud region, this agreement marks a decisive step in meeting the German market's demand for sovereign solutions that shield sensitive data from extraterritorial laws. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520279285/en/ The wholly-owned subsidiary of Thales in Germany offers an independent cloud solution based on Google Cloud technology. © Thales/Google Cloud Thales will launch a new German entity, legally and operationally independent from Google Cloud, that will be staffed and managed by local German personnel, ensuring that no third party, including non-European entities, can access the data stored or processed within it. “Germany re
Klarna launches AI-powered Shopping Search app in ChatGPT20.5.2026 14:30:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, today launched the Klarna Shopping Search app in ChatGPT, bringing real-time product discovery directly into the conversation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520024278/en/ The Klarna Shopping Search app is live in ChatGPT The launch comes as AI-powered product search reshapes online retail: during the 2025 holiday season, traffic from AI platforms to retail sites grew nearly 700%, with those shoppers converting at 31% higher rates. Until now, consumers asking AI models for shopping help have had to open new browser tabs, navigate competing sites, and reconcile outdated prices. With the Klarna Shopping Search app in ChatGPT, they simply describe what they're looking for and instantly see visual results with up-to-date prices, availability, and offers from multiple merchants, all within the same conversation. The Klarna Shopping Search app then
IAMPHENOM Europe 2026 Registration Opens: HR’s Leading Conference for Agentic AI Learning Returns20.5.2026 14:00:00 EEST | Press release
Phenom, the leader in applied AI with an infrastructure built specifically to redesign work operations, today announced registration is open for IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. The only applied AI event dedicated to human resources on the continent, IAMPHENOM Europe gives HR and HRIT leaders the agentic AI strategies, instruction and proof points they need to build their AI-augmented workforce to address their biggest hiring, development and retention challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520683492/en/ Phenom today announced registration is open for IAMPHENOM Europe 2026. The only applied AI event dedicated to human resources on the continent is taking place 4-5 November in Paris, France. European organisations face pressure from every direction, including widening skills shortages, tightening EU AI Act compliance and competitors moving faster with AI than HR teams c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom